Erica has wanted to be a travel writer since college and now as a mom of two, she's finally pursuing that dream. She takes pride in researching the best trip information and test driving the recommendations you'll find on this site. When she's not immersed in travel research you can find her with her kids or attempting to learn tennis (advice accepted!).
The sector is dominated by a small group of multinational corporations.
Significant efforts are underway to align U.S. drug prices with lower international rates.
Eli Lilly, Johnson & Johnson, AbbVie, and Roche are among the largest global players.
"Big Pharma" refers to the world's largest publicly traded pharmaceutical companies. As of late 2025, the industry is navigating significant regulatory changes, particularly in the United States, where the Trump administration has been pressuring major manufacturers to lower prescription costs through "Most-Favored-Nation" (MFN) pricing. Market Leaders and Ownership
A significant portion of these companies is owned by large institutional investors like Blackrock, Vanguard, and State Street, which collectively hold roughly 20% of the industry.
Key drugs driving recent revenue include semaglutide (Ozempic/Wegovy) from Novo Nordisk and various high-cost therapies for chronic conditions. Current Pricing and Regulatory Trends